6 results on '"Bunse, Theresa"'
Search Results
2. Genetically Modified Cellular Therapies for Malignant Gliomas.
- Author
-
Kilian, Michael, Bunse, Theresa, Wick, Wolfgang, Platten, Michael, and Bunse, Lukas
- Subjects
- *
T cells , *T cell receptors , *IMMUNE checkpoint inhibitors , *CELLULAR therapy , *GLIOMAS , *BRAIN tumors , *NUCLEOTIDE sequencing - Abstract
Despite extensive preclinical research on immunotherapeutic approaches, malignant glioma remains a devastating disease of the central nervous system for which standard of care treatment is still confined to resection and radiochemotherapy. For peripheral solid tumors, immune checkpoint inhibition has shown substantial clinical benefit, while promising preclinical results have yet failed to translate into clinical efficacy for brain tumor patients. With the advent of high-throughput sequencing technologies, tumor antigens and corresponding T cell receptors (TCR) and antibodies have been identified, leading to the development of chimeric antigen receptors (CAR), which are comprised of an extracellular antibody part and an intracellular T cell receptor signaling part, to genetically engineer T cells for antigen recognition. Due to efficacy in other tumor entities, a plethora of CARs has been designed and tested for glioma, with promising signs of biological activity. In this review, we describe glioma antigens that have been targeted using CAR T cells preclinically and clinically, review their drawbacks and benefits, and illustrate how the emerging field of transgenic TCR therapy can be used as a potent alternative for cell therapy of glioma overcoming antigenic limitations. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
3. A Cellular Ground Truth to Develop MRI Signatures in Glioma Models by Correlative Light Sheet Microscopy and Atlas-Based Coregistration.
- Author
-
Schregel, Katharina, Heinz, Lennart, Hunger, Jessica, Chenchen Pan, Bode, Julia, Fischer, Manuel, Sturm, Volker, Venkataramani, Varun, Karimian-Jazi, Kianush, Agardy, Dennis A., Streibel, Yannik, Zerelles, Roland, Wick, Wolfgang, Heiland, Sabine, Bunse, Theresa, Tews, Björn, Platten, Michael, Winkler, Frank, Bendszus, Martin, and Breckwoldt, Michael O.
- Subjects
- *
MICROSCOPY , *DIFFUSION tensor imaging , *DIFFUSION magnetic resonance imaging , *MAGNETIC resonance imaging , *IMAGE analysis , *GLIOMAS - Abstract
Glioblastoma is the most common malignant primary brain tumor with poor overall survival. Magnetic resonance imaging (MRI) is the main imaging modality for glioblastoma but has inherent shortcomings. The molecular and cellular basis of MR signals is incompletely understood. We established a ground truth-based image analysis platform to coregister MRI and light sheet microscopy (LSM) data to each other and to an anatomic reference atlas for quantification of 20 predefined anatomic subregions. Our pipeline also includes a segmentation and quantification approach for single myeloid cells in entire LSM datasets. This method was applied to three preclinical glioma models in male and female mice (GL261, U87MG, and S24), which exhibit different key features of the human glioma. Multiparametric MR data including T2-weighted sequences, diffusion tensor imaging, T2 and T2* relaxometry were acquired. Following tissue clearing, LSM focused on the analysis of tumor cell density, microvasculature, and innate immune cell infiltration. Correlated analysis revealed differences in quantitative MRI metrics between the tumor-bearing and the contralateral hemisphere. LSM identified tumor subregions that differed in their MRI characteristics, indicating tumor heterogeneity. Interestingly, MRI signatures, defined as unique combinations of different MRI parameters, differed greatly between the models. The direct correlation of MRI and LSM allows an in-depth characterization of preclinical glioma and can be used to decipher the structural, cellular, and, likely, molecular basis of tumoral MRI biomarkers. Our approach may be applied in other preclinical brain tumor or neurologic disease models, and the derived MRI signatures could ultimately inform image interpretation in a clinical setting. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. K27M-mutant histone-3 as a novel target for glioma immunotherapy.
- Author
-
Ochs, Katharina, Ott, Martina, Bunse, Theresa, Sahm, Felix, Bunse, Lukas, Deumelandt, Katrin, Sonner, Jana K., Keil, Melanie, von Deimling, Andreas, Wick, Wolfgang, and Platten, Michael
- Subjects
- *
IMMUNOTHERAPY , *GLIOMAS , *HISTONES - Abstract
Mutation-specific vaccines have become increasingly important in glioma immunotherapy; however, shared neoepitopes are rare. For diffuse gliomas, a driver mutation in the gene for isocitrate dehydrogenase type-1 has been shown to produce an immunogenic epitope currently targeted in clinical trials. For highly aggressive midline gliomas, a recurrent point mutation in the histone-3 gene (H3F3A) causes an amino acid change from lysine to methionine at position 27 (K27M). Here, we demonstrate that a peptide vaccine against K27M-mutant histone-3 is capable of inducing effective, mutation-specific, cytotoxic T-cell- and T-helper-1-cell-mediated immune responses in a major histocompatibility complex (MHC)-humanized mouse model. By proving an immunologically effective presentation of the driver mutation H3K27M on MHC class II in human H3K27M-mutant gliomas, our data provide a basis for the further clinical development of vaccine-based or cell-based immunotherapeutic approaches targeting H3K27M. [ABSTRACT FROM PUBLISHER]
- Published
- 2017
- Full Text
- View/download PDF
5. Concepts in glioma immunotherapy.
- Author
-
Platten, Michael, Bunse, Lukas, Wick, Wolfgang, and Bunse, Theresa
- Subjects
- *
GLIOMA treatment , *CANCER immunotherapy , *TUMOR antigens , *CANCER vaccines , *ANTINEOPLASTIC agents - Abstract
Immunotherapeutic concepts in neurooncology have been developed for many decades but have mainly been hampered by poor definition of relevant antigens and selective measures to target the central nervous system. Independent of the recent remarkable successes in clinical immunooncology with checkpoint inhibitors and vaccines, immunotherapy of brain tumors in general and gliomas in particular has evolved with novel neurooncology-specific concepts over the past years providing new phase 1 approaches of individualized immunotherapy to first phase three clinical trials. These concepts are driven by a high medical need in the absence of approved targeted therapies and refute the classic dogma that the central nervous system is immune-privileged and hence inaccessible to potent antitumor immunity. Instead, measures have been taken to improve the odds for successful immunotherapies, including rational targeting of relevant antigens and integration of immunotherapies into standard of care primary radiochemotherapy to increase the efficacy of antitumor immunity in a meaningful time window. This review highlights concepts and challenges associated with epitope discovery and selection and trial design. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
6. General control non-derepressible 2 (GCN2) in T cells controls disease progression of autoimmune neuroinflammation.
- Author
-
Keil, Melanie, Sonner, Jana K., Lanz, Tobias V., Oezen, Iris, Bunse, Theresa, Bittner, Stefan, Meyer, Hannah V., Meuth, Sven G., Wick, Wolfgang, and Platten, Michael
- Subjects
- *
MULTIPLE sclerosis , *T cells , *AUTOIMMUNE diseases , *DISEASE progression , *NEUROLOGICAL disorders , *INFLAMMATION - Abstract
Relapsing-remitting multiple sclerosis (MS) 2 2 MS: multiple sclerosis. is characterized by phases of acute neuroinflammation followed by spontaneous remission. Termination of inflammation is accompanied by an influx of regulatory T cells (T regs ). 3 3 T regs : regulatory T cells. The molecular mechanisms responsible for directing T regs into the inflamed CNS tissue, however, are incompletely understood. In an MS mouse model we show that the stress kinase general control non-derepressible 2 (GCN2), 4 4 GCN2: general control non-derepressible 2. expressed in T cells, contributes to the resolution of autoimmune neuroinflammation. Failure to recover from acute inflammation was associated with reduced frequencies of CNS-infiltrating T regs . GCN2 deficient T regs displayed impaired migration to a CCL2 gradient. These data suggest an important contribution of the T cell stress response to the resolution of autoimmune neuroinflammation. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.